An observational study in Coronary Artery Stenosis and Coronary Artery Disease, sponsored by Seung-Jung Park. Recruiting at 11 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.
Sponsored by Seung-Jung Park · Observational
The objective of this study is to evaluate the effectiveness and safety of Coroflex ISAR NEO stents in comparison to other drug-eluting stents (DES) in real-world practice.
326 studies on the registry are indexed under Coronary Stenosis; 57 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 125 observational studies indexed under Coronary Stenosis.
Browse Coronary Stenosis studies →Seung-Jung Park is the lead sponsor of 82 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients receiving Coroflex ISAR NEO stents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving percutaneous coronary intervention with Coroflex ISAR NEO stents
Device: Coroflex ISAR NEO stent
Percutaneous coronary intervention with Coroflex ISAR NEO stent
the composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)
the composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR) at 12 months post procedure. A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event is considered to have occurred if any one of several different events is observed.
Time frame: 12 months
the event rate of all cause death
Time frame: 5 years
the event rate of cardiac death
Time frame: 5 years
the event rate of myocardial infarction
Time frame: 5 years
the composite event rate of death, or myocardial infarction (MI)
Time frame: 5 years
the composite event rate of cardiac death, or myocardial infarction (MI)
Time frame: 5 years
the event rate of Target- Vessel Revascularization (TVR)
Time frame: 5 years
the event rate of Target- lesion Revascularization (TLR)
Time frame: 5 years
the event rate of stent thrombosis
according to an Academic Research Consortium (ARC) criteria
Time frame: 5 years
the event rate of stroke
Time frame: 5 years
the event rate of Procedural success
defined as achievement of a final diameter stenosis of \<30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization.
Time frame: 5 days
Not enrolling at this site.
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seung-Jung Park